SCHEMBL1463376

SCHEMBL1463376

[CH2]C(=O)Nc1cccc(-c2cnc3ccccc3n2)c1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.76
NPC1 O15118 4/20 0.76
TP53 P04637 1/20 0.76
STAT1 P42224 1/20 0.76
SMN1; SMN2 Q16637 1/20 0.76
JAK3 P52333 8/20 0.75
KMT2A Q03164 7/20 0.73
MAPT P10636 4/20 0.71
ALDH1A1 P00352 2/20 0.71
HTT P42858 2/20 0.71
MITF O75030 1/20 0.71
LMNA P02545 1/20 0.71
JAK2 O60674 4/20 0.70
MEN1 O00255 6/20 0.67
CYP1A2 P05177 3/20 0.67
CYP3A4 P08684 3/20 0.67
CYP2C9 P11712 3/20 0.67
CYP2C19 P33261 2/20 0.67
NPSR1 Q6W5P4 1/20 0.67
TDP1 Q9NUW8 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1462289 0.86 JAK3 (1.00) RAB9ANPC1TP53STAT1SMN1; SMN2
SCHEMBL1463310 0.84 JAK3 (0.80) RAB9ANPC1TP53STAT1SMN1; SMN2
SCHEMBL12746080 0.84 RAB9A (0.77) RAB9ANPC1TP53STAT1SMN1; SMN2
SCHEMBL3711579 0.83 JAK3 (0.78) RAB9ANPC1TP53STAT1SMN1; SMN2
SCHEMBL1462349 0.83 JAK3 (1.00) RAB9ANPC1TP53STAT1SMN1; SMN2
SCHEMBL1462316 0.83 RAB9A (1.00) RAB9ANPC1TP53STAT1SMN1; SMN2
SCHEMBL1463421 0.83 JAK3 (1.00) RAB9ANPC1TP53STAT1SMN1; SMN2
SCHEMBL1463316 0.83 JAK3 (1.00) RAB9ANPC1TP53STAT1SMN1; SMN2
SCHEMBL1464227 0.83 JAK3 (0.73) RAB9ANPC1TP53STAT1SMN1; SMN2
SCHEMBL1463399 0.82 JAK2 (1.00) RAB9ANPC1TP53STAT1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2396004-A1 SELECTIVE KINASE INHIBITORS Reaction Biology Corp. (US) 2011-12-21 EP claimed
US-20110071149-A1 SELECTIVE KINASE INHIBITORS REACTION BIOLOGY CORP. (US) 2011-03-24 US claimed
WO-2010093808-A1 SELECTIVE KINASE INHIBITORS REACTION BIOLOGY CORP. (US) 2010-08-19 WO claimed
US-8592415-B2 Selective kinase inhibitors REACTION BIOLOGY CORP. (US) 2013-11-26 US disclosed
EP-2396004-A1 SELECTIVE KINASE INHIBITORS Reaction Biology Corp. (US) 2011-12-21 EP disclosed
US-20110071149-A1 SELECTIVE KINASE INHIBITORS REACTION BIOLOGY CORP. (US) 2011-03-24 US disclosed
WO-2010093808-A1 SELECTIVE KINASE INHIBITORS REACTION BIOLOGY CORP. (US) 2010-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071149-A1 SELECTIVE KINASE INHIBITORS JAK3, JAK1, JAK2 RAB9A 1139/4885NPC1 3267/4885TP53 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.